Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2004-11-09

Last Posted Date: 2018-12-04

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 31

Registration Number: NCT00096343

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Dysphagia
Lung Cancer

Interventions: Drug: Placebo
Drug: Palifermin
Radiation: Radiotherapy
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2004-10-27

Last Posted Date: 2017-03-14

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 100

Registration Number: NCT00094861

Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Cancer
Non-Small Cell Lung Cancer

Interventions: Biological: Panitumumab
Drug: Motesanib diphosphate
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2004-10-27

Last Posted Date: 2016-03-24

Lead Sponsor: Amgen

Target Recruit Count: 51

Registration Number: NCT00094835

Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Docetaxel
Drug: Gemcitabine
Drug: Doxorubicin

First Posted Date: 2004-10-08

Last Posted Date: 2018-01-11

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 4894

Registration Number: NCT00093795

Locations: 🇺🇸
Chestnut Hill Healthcare Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States
🇺🇸
Providence Cancer Center, Anchorage, Alaska, United States

and more 9 locations

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer

Interventions: Radiation: 3-dimensional conformal radiation therapy
Drug: bortezomib
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2004-10-08

Last Posted Date: 2017-12-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT00093756

Locations: 🇺🇸
Mcdonough District Hospital, Macomb, Illinois, United States
🇺🇸
Carle Foundation - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States

and more 139 locations

Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-09-14

Last Posted Date: 2013-07-10

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004089

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2004-09-13

Last Posted Date: 2013-11-13

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 122

Registration Number: NCT00003591

Locations: 🇺🇸
Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
🇺🇸
MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States
🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States

and more 231 locations

Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

Phase 1

Completed

Conditions: Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-09-13

Last Posted Date: 2013-06-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT00004057

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: cisplatin
Drug: gemcitabine
Drug: docetaxel
Drug: paclitaxel
Drug: vinorelbine

First Posted Date: 2004-09-13

Last Posted Date: 2012-10-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 204

Registration Number: NCT00003587

Locations: 🇺🇸
CCOP - Montana Cancer Consortium, Billings, Montana, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 81 locations

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer
Ovarian Cancer

Interventions: Drug: cisplatin
Drug: paclitaxel
Drug: phenoxodiol

First Posted Date: 2004-09-09

Last Posted Date: 2016-07-14

Lead Sponsor: MEI Pharma, Inc.

Target Recruit Count: 65

Registration Number: NCT00091377

Locations: 🇦🇺
Royal Women's Hospital, Carlton, Victoria, Australia
🇺🇸
Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy